Disparities in liver cancer occurrence in the United Stat

Ca-A Cancer Journal for Clinicians
67, 273-289
DOI: 10.3322/caac.21402

Citation Report

#	Article	IF	Citations
1	Early estimates of cancer incidence for 2015: Expanding to include estimates for white and black races. Cancer, 2018, 124, 2192-2204.	2.0	9
2	Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983â€“2007) and Predictions to 2030. Gastroenterology, 2018, 154, 1719-1728.e5.	0.6	70
3	Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. Ca-A Cancer Journal for Clinicians, 2018, 68, 31-54.	157.7	970
4	Epidemiological trends in digestive cancers compared to trends in alcohol consumption. Facts from Romania: correlation or coincidence?. Medicine and Pharmacy Reports, 2018, 91, 376-386.	0.2	2
5	Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes. American Journal of Preventive Medicine, 2018, 55, S40-S48.	1.6	35
6	MicroRNAâ€‘29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression. Oncology Letters, 2018, 16, 1543-1550.	0.8	4
7	Evaluation of the influence of green extraction solvents on the cytotoxic activities of Crinum (Amaryllidaeae) alkaloid extracts using in-vitro-in-silico approach. Journal of Ethnopharmacology, 2018, 227, 139-149.	2.0	16
8	Liver cancer mortality trends in South Africa: 1999â€“2015. BMC Cancer, 2018, 18, 798.	1.1	15
9	NEAT1 upregulates TGFâ€Î²1 to induce hepatocellular carcinoma progression by sponging hsaâ€mirâ€139â€5p. Journal of Cellular Physiology, 2018, 233, 8578-8587.	2.0	56
10	Lentinan relieves hepatitis B surface antigen induced functional impairment of monocytes/macrophages. Tropical Journal of Pharmaceutical Research, 2018, 17, 583.	0.2	1
11	Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. Frontiers in Oncology, 2018, 8, 220.	1.3	11
12	An assessment of progress in cancer control. Ca-A Cancer Journal for Clinicians, 2018, 68, 329-339.	157.7	145
13	Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. Cancers, 2018, 10, 101.	1.7	53
14	Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in <scp>C</scp>alifornia: Implications for prevention. Cancer, 2018, 124, 3551-3559.	2.0	20
15	MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/Î²-catenin signaling. Biomedicine and Pharmacotherapy, 2018, 107, 754-762.	2.5	33
16	CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology, 2019, 69, 143-159.	3.6	105
17	Identification of metabolism-associated pathways and genes involved in male and female liver cancer patients. Journal of Theoretical Biology, 2019, 480, 218-228.	0.8	10
18	The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages. International Journal of Epidemiology, 2019, 48, 1886-1896.	0.9	9

#	Article	IF	Citations
19	Patterns and co-occurrence of risk factors for hepatocellular carcinoma in four Asian American communities: a cross-sectional study. BMJ Open, 2019, 9, e026409.	0.8	7
20	Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduction and Targeted Therapy, 2019, 4, 41.	7.1	150
21	Racial disparities in alphaâ€fetoprotein testing and alphaâ€fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Medicine, 2019, 8, 6614-6623.	1.3	9
22	Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992â€“2016. Cancer Causes and Control, 2019, 30, 1377-1388.	0.8	15
23	A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease. Biochemistry, 2019, 58, 3911-3917.	1.2	3
24	LncSNHG3/miR-139-5p/BMI1 axis regulates proliferation, migration, and invasion in hepatocellular carcinoma . OncoTargets and Therapy, 2019, Volume 12, 6623-6638.	1.0	34
25	Emerging Evidence for Infectious Causes of Cancer in the United States. Epidemiologic Reviews, 2019, 41, 82-96.	1.3	6
26	Scutellarin inhibits proliferation and invasion of hepatocellular carcinoma cells via downâ€regulation of JAK2/STAT3 pathway. Journal of Cellular and Molecular Medicine, 2019, 23, 3040-3044.	1.6	48
27	Novel nanosized AS1411â€“chitosanâ€“BODIPY conjugate for molecular fluorescent imaging . International Journal of Nanomedicine, 2019, Volume 14, 3543-3555.	3.3	11
28	Predicting hepatocellular carcinoma recurrences: A data-driven multiclass classification method incorporating latent variables. Journal of Biomedical Informatics, 2019, 96, 103237.	2.5	5
29	Roles of mitochondria in liver cancer stem cells. Differentiation, 2019, 107, 35-41.	1.0	19
30	Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2â€ T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine, 2019, 44, 209-224.	2.7	31
31	Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy. Biomaterials, 2019, 216, 119220.	5.7	89
32	Receptorâ€Interacting Protein Kinase 3 Deficiency Recruits Myeloidâ€Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (Câ€Xâ€C Motif) Ligand 1â€“Chemokine (Câ€Xâ€C Motif) Receptor 2 Axis. Hepatology, 2019, 70, 1564-1581.	3.6	48
33	Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. Journal of Surgical Research, 2019, 241, 31-39.	0.8	9
34	The Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South Texas. Journal of Oncology Practice, 2019, 15, 61-63.	2.5	8
35	Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miRâ€5095 from MBD2. Journal of Cellular Physiology, 2019, 234, 18504-18512.	2.0	4
36	Dysregulated transmethylation leading to hepatocellular carcinoma compromises redox homeostasis and glucose formation. Molecular Metabolism, 2019, 23, 1-13.	3.0	8

#	Article	IF	Citations
37	Temporal trends in liver cancer mortality by educational attainment in the United States, 2000â€2015. Cancer, 2019, 125, 2089-2098.	2.0	12
38	Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells. Hormone Molecular Biology and Clinical Investigation, 2019, 38, .	0.3	9
39	Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 486-494.	1.1	19
40	Insight into hepatitis B prevalence and risk factors among Vietnamese Americans: a cross-sectional analysis of data from a community-based screening program. BMJ Open, 2019, 9, e029616.	0.8	6
41	Potential of Ablation Therapy during Hepatocellular Carcinoma. Nutrition and Cancer, 2019, 71, 881-885.	0.9	3
42	Trends in liver cancer mortality in the United States: Dual burden among foreignâ€•and USâ€born persons. Cancer, 2019, 125, 726-734.	2.0	33
43	Surgical Delay Is Associated with Improved Survival in Hepatocellular Carcinoma: Results of the National Cancer Database. Journal of Gastrointestinal Surgery, 2019, 23, 933-943.	0.9	13
44	Clinical workup of fatty liver for the primary care provider. Postgraduate Medicine, 2019, 131, 19-30.	0.9	4
45	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011â€“2015 update. Journal of Gastroenterology, 2019, 54, 367-376.	2.3	156
46	Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. Cancer Research, 2020, 80, 561-575.	0.4	27
47	Pulmonary metastases in newly diagnosed hepatocellular carcinoma: a population-based retrospective study. Hpb, 2020, 22, 1295-1304.	0.1	6
48	Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and metaâ€analysis. Cancer Medicine, 2020, 9, 1349-1364.	1.3	30
49	Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. Journal of Gastrointestinal Surgery, 2020, 24, 2737-2747.	0.9	21
50	NFAT2 overexpression suppresses the malignancy of hepatocellular carcinoma through inducing Egr2 expression. BMC Cancer, 2020, 20, 966.	1.1	11
51	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	0.8	350
52	The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1017-1024.	1.4	14
53	6,8-Diprenylorobol Induces Apoptosis in Human Hepatocellular Carcinoma Cells via Activation of FOXO3 and Inhibition of CYP2J2. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-19.	1.9	13
54	Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 602542.	1.1	7

#	Article	IF	Citations
55	Regulatory Mechanisms of Coicis Semen on Bionetwork of Liver Cancer Based on Network Pharmacology. BioMed Research International, 2020, 2020, 1-17.	0.9	6
56	Liver Cancer Incidence and Area-Level Geographic Disparities in Pennsylvaniaâ€"A Geo-Additive Approach. International Journal of Environmental Research and Public Health, 2020, 17, 7526.	1.2	5
57	The changing landscape of cancer in the USA â€" opportunities for advancing prevention and treatment. Nature Reviews Clinical Oncology, 2020, 17, 631-649.	12.5	32
58	Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Translational Cancer Research, 2020, 9, 128-136.	0.4	2
59	Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically. Gut Microbes, 2020, 11, 1450-1474.	4.3	71
60	Hepatitis B virus American genotypes: Pathogenic variants ?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 825-835.	0.7	24
61	Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Ageâ€"Periodâ€"Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 88-94.	1.1	27
62	Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 171.	1.3	139
63	Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. Molecules, 2020, 25, 645.	1.7	9
64	The significance of arginase-1 expression in the diagnosis of liver cancer. Medicine (United States), 2020, 99, e19159.	0.4	1
65	Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology, 2020, 158, 1503-1505.e2.	0.6	36
66	Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 300-307.	1.1	15
67	Diagnostic and Prognostic Values of MANF Expression in Hepatocellular Carcinoma. BioMed Research International, 2020, 2020, 1-18.	0.9	10
68	HRC promotes anoikis resistance and metastasis by suppressing endoplasmic reticulum stress in hepatocellular carcinoma. International Journal of Medical Sciences, 2021, 18, 3112-3124.	1.1	7
69	Declining US Hepatocellular Carcinoma Rates, 2014â€"2017. Clinical Gastroenterology and Hepatology, 2022, 20, e330-e334.	2.4	9
70	Impact of statin use on the risk and prognosis of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 1603-1609.	0.8	6
71	Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Scientific Reports, 2021, 11, 6069.	1.6	12
72	Sex and Race-Related DNA Methylation Changes in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 3820.	1.8	15

#	Article	IF	Citations
74	Effects of propofol on the proliferation and migration of liver cancer cells. Experimental and Therapeutic Medicine, 2021, 22, 733.	0.8	2
75	SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death and Disease, 2021, 12, 570.	2.7	20
76	Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 232-239.	0.6	11
77	Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists. Medical Care, 2021, Publish Ahead of Print, 699-703.	1.1	1
78	lncRNA LOXL1â€'AS1 promotes liver cancer cell proliferation and migration by regulating the miRâ€'377â€'3p/NFIB axis. Oncology Letters, 2021, 22, 624.	0.8	14
79	Building Capacity for Global Cancer Research: Existing Opportunities and Future Directions. Journal of Cancer Education, 2021, 36, 5-24.	0.6	10
80	Racial Differences in Hepatocellular Carcinoma Incidence and Risk Factors among a Low Socioeconomic Population. Cancers, 2021, 13, 3710.	1.7	4
81	Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 5162-5179.	1.0	9
82	Trends in the Incidence of Hepatocellular Carcinoma in Washington DC: A Single Institutional Cohort Study (1959â€"2013). Journal of the National Medical Association, 2021, 113, 396-404.	0.6	0
83	Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Medicine, 2021, 10, 7347-7359.	1.3	8
84	Integrative Analysis of DNA Methylation and microRNA Expression Reveals Mechanisms of Racial Heterogeneity in Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 708326.	1.1	5
85	Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1. BMC Cancer, 2021, 21, 1063.	1.1	3
86	Cancer death and potential years of life lost in Feicheng City, China. Medicine (United States), 2021, 100, e27370.	0.4	1
87	Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity. PLoS ONE, 2021, 16, e0257072.	1.1	8
88	Cancer mortality in a population-based cohort of American Indians â€" The strong heart study. Cancer Epidemiology, 2021, 74, 101978.	0.8	3
89	The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007â€2017. Hepatology Communications, 2021, 5, 749-759.	2.0	25
90	Liver Cytology. , 2018, , 173-198.		1
91	A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatology International, 2020, 14, 1034-1047.	1.9	42

#	Article	IF	Citations
92	An overview of cancer health disparities: new approaches and insights and why they matter. Carcinogenesis, 2021, 42, 2-13.	1.3	39
93	Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS ONE, 2017, 12, e0189255.	1.1	47
94	Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling. Oncotarget, 2017, 8, 114945-114955.	0.8	25
95	Cancer burden in the United Statesâ€"a review. Annals of Cancer Epidemiology, 0, 1, 1-1.	1.8	5
96	Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 571-579.	0.7	224
97	Precision Medicine in Non Communicable Diseases. International Journal of Molecular and Cellular Medicine, 2019, 8, 1-18.	1.1	4
98	Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 729-736.	2.3	4
99	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	2.3	477
100	Serum KLKB1 as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Based on Data-Independent Acquisition and Parallel Reaction Monitoring. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1241-1252.	1.8	11
101	Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy. Cureus, 2018, 10, e3714.	0.2	1
102	Smoking, Implications of. , 2020, , 492-498.		0
103	Downregulated Mucin 1 alleviates paclitaxel resistance in nonâ€'small cell lung cancer cells. Molecular Medicine Reports, 2020, 22, 2966-2972.	1.1	4
104	MicroRNA regulation of liver cancer stem cells. American Journal of Cancer Research, 2018, 8, 1126-1141.	1.4	54
105	YY1-mediated reticulocalbin-2 upregulation promotes the hepatocellular carcinoma progression via activating MYC signaling. American Journal of Cancer Research, 2021, 11, 2238-2251.	1.4	0
106	Liver cancer incidence and mortality: Disparities based on age, ethnicity, health and nutrition, molecular factors, and geography. Cancer Health Disparities, 2020, 4, e1-e10.	0.5	0
107	The Effect of 5A nursing intervention on living quality and self-care efficacy of patients undergoing chemotherapy after hepatocellular carcinoma surgery. American Journal of Translational Research (discontinued), 2021, 13, 6638-6645.	0.0	0
108	Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Frontiers in Physiology, 2021, 12, 715536.	1.3	11
109	Fabrication of Size-Controllable and Arrangement-Orderly HepG2 Spheroids for Drug Screening via Decellularized Liver Matrix-Derived Micropattern Array Chips. ACS Omega, 2022, 7, 2364-2376.	1.6	13

#	Article	IF	Citations
110	Prediction of Microvascular Invasion and Its M2 Classification in Hepatocellular Carcinoma Based on Nomogram Analyses. Frontiers in Oncology, 2021, 11, 774800.	1.3	2
111	Generation of a nanobody-alkaline phosphatase heptamer fusion for ratiometric fluorescence immunodetection of trace alpha fetoprotein in serum. International Journal of Biological Macromolecules, 2022, 201, 507-515.	3.6	17
112	Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis. Frontiers in Oncology, 2022, 12, 855952.	1.3	3
113	Multidimensional Analysis of CHMP Family Members in Hepatocellular Carcinoma. International Journal of General Medicine, 2022, Volume 15, 2877-2894.	0.8	4
114	Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1402-1409.	1.1	7
115	Advancing Liver Cancer Prevention for American Indian Populations in Arizona: An Integrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 3268.	1.2	2
116	Risk Factors on the Incidence and Prognostic Effects of Colorectal Cancer With Brain Metastasis: A SEER-Based Study. Frontiers in Oncology, 2022, 12, 758681.	1.3	1
117	TARE and PVE as pre-operative strategies in highly selected patients with primary and metastatic hepatic malignancies. International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
118	Mechanism of HBV-positive liver cancer cell exosomal miR-142-3p by inducing ferroptosis of M1 macrophages to promote liver cancer progression. Translational Cancer Research, 2022, 11, 1173-1187.	0.4	12
138	Neoplasias relacionadas ao tabaco: anÃ¡lise de sobrevivÃªncia e risco de Ã³bito de dados populacionais de FlorianÃ³polis, SC. Revista De Saude Publica, 2022, 56, 16.	0.7	3
139	Disparities in risk of advanced stage liver cancer and mortality by race and ethnicity. Journal of the National Cancer Institute, 2022, , .	3.0	0
140	Racial and ethnic disparities in incidence and mortality for the five most common gastrointestinal cancers in the United States. Journal of the National Medical Association, 2022, 114, 426-429.	0.6	4
141	Trends in Cancer Mortality Among Black Individuals in the US From 1999 to 2019. JAMA Oncology, 2022, 8, 1184.	3.4	33
142	Process evaluation of an academic-community-government partnership to reduce liver diseases attributable to hepatitis B virus. BMC Health Services Research, 2022, 22, .	0.9	0
143	Machine Learning Approach to Facilitate Knowledge Synthesis at the Intersection of Liver Cancer, Epidemiology, and Health Disparities Research. JCO Clinical Cancer Informatics, 2022, , .	1.0	0
144	Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo. Pharmaceuticals, 2022, 15, 716.	1.7	2
145	Air pollution and liver cancer: A systematic review. Journal of Environmental Sciences, 2023, 126, 817-826.	3.2	4
146	Fat and exposure to 4-nitroquinoline-1-oxide causes histologic and inflammatory changes in murine livers. PLoS ONE, 2022, 17, e0268891.	1.1	0

#	Article	IF	Citations
147	A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	3
148	Using Period Analysis to Timely Assess and Predict 5-Year Relative Survival for Liver Cancer Patients From Taizhou, Eastern China. Frontiers in Oncology, 0, 12, .	1.3	2
149	Association Between Socioeconomic and Insurance Status and Delayed Diagnosis of Gastrointestinal Cancers. Journal of Surgical Research, 2022, 279, 170-186.	0.8	6
150	Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome. Frontiers in Oncology, 0, 12, .	1.3	1
151	The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	15
152	Risk prediction model for early postoperative death in patients with hepatocellular carcinoma: a retrospective study based on random forest algorithm and logistic regression. European Journal of Gastroenterology and Hepatology, 0, Publish Ahead of Print, .	0.8	1
153	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology, 2022, 29, 6445-6462.	0.9	6
154	Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy, 2023, 19, 1184-1198.	4.3	15
155	Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	4
156	Cancer statistics for<scp>A</scp>merican<scp>I</scp>ndian and<scp>A</scp>laska<scp>N</scp>ative individuals, 2022: Including increasing disparities in early onset colorectal cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 120-146.	157.7	39
157	Understanding the Changing Landscape of Health Disparities in Chronic Liver Diseases and Liver Cancer. , 2023, 2, 505-520.		1
158	Impact of Race and Neighborhood Socioeconomic Characteristics on Liver Cancer Diagnosis in Patients with Viral Hepatitis and Cirrhosis. Journal of Clinical and Experimental Hepatology, 2023, , .	0.4	0
159	New insights into a microvascular invasion prediction model in hepatocellular carcinoma: A retrospective study from the SEER database and China. Frontiers in Surgery, 0, 9, .	0.6	2
160	Secular Trends of Liver Cancer Mortality and Years of Life Lost in Wuhan, China 2010â€“2019. Current Oncology, 2023, 30, 938-948.	0.9	0
161	Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study. PLoS ONE, 2023, 18, e0267809.	1.1	1
163	Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database. Journal of Gastrointestinal Oncology, 2023, 14, 312-324.	0.6	2
170	Cancer-related cognitive impairment in racial and ethnic minority groups: a scoping review. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
174	Cancer burden: Epidemiology, racial, and geographical disparities. , 2024, , 15-32.		0

#	Article	IF	Citations